SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Akums Drugs and Pharmaceuticals informs about press release

11 Nov 2024 Evaluate
Akums Drugs and Pharmaceuticals has informed that it enclosed a copy of Newspaper publications of unaudited financial results for the quarter and half year ended September 30, 2024 published today in the following newspapers. Financial Express, New Delhi; Jansatta, New Delhi

The above information is a part of company’s filings submitted to BSE.

Akums Drugs & Pharma Share Price

658.00 11.55 (1.79%)
09-Jul-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1938.85
Dr. Reddys Labs. 1269.80
Cipla 1441.70
Zydus Lifesciences 1159.85
Lupin 2504.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: